1492 Capital Management LLC bought a new position in ANI Pharmaceuticals, Inc. during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. ANI Pharmaceuticals accounts for 1.9% of 1492 Capital Management LLCs portfolio, making the stock its 24th largest position. 1492 Capital Management LLC owned..
By a News Reporter-Staff News Editor at Investment Weekly News Research and Markets has announced the addition of the "3rd Anti-Counterfeiting Pharma Conference 2017" conference to their offering. As per the 2016 International Trade Administration Top Market Reports on Pharmaceuticals, estimates on the size of the global Fake Drugs market range f
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Paris, 8 December 2016- ABIVAX, an innovative biotechnology company targeting the immune system to eliminate viral disease, announced that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/A
AcelRx Pharmaceuticals Inc. has been assigned a consensus rating of Buy from the nine ratings firms that are currently covering the stock. Roth Capital set a $15.00 target price on AcelRx Pharmaceuticals and gave the company a buy rating in a research note on Saturday, October 15th. Cowen and Company restated a hold rating on shares of AcelRx Pharm
Analyst Ratings For Syndax Pharmaceuticals (NASDAQ:SNDX) Today, BTIG Research initiated coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy with a price target of $25.80. There are 6 buy ratings on the stock. The current consensus rating on Syndax Pharmaceuticals (NASDAQ:SNDX) is Buy (Score: 3.00) with a consensus target price of $25.80 per
Analyst Ratings For Aurinia Pharmaceuticals (NASDAQ:AUPH) Today, HC Wainwright lowered its price target on Aurinia Pharmaceuticals (NASDAQ:AUPH) to $8.00 per share. There are 6 buy ratings on the stock. The current consensus rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) is Buy (Score: 3.00) with a consensus target price of $8.40 per share, a pote
Analyst Ratings For Pacira Pharmaceuticals (NASDAQ:PCRX) Today, Janney Montgomery Scott raised its price target on Pacira Pharmaceuticals (NASDAQ:PCRX) to $34.00 per share. There are 6 hold ratings, 7 buy ratings on the stock. The current consensus rating on Pacira Pharmaceuticals (NASDAQ:PCRX) is Buy (Score: 2.54) with a consensus target price of
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Castle Creek Pharmaceuticals, LLC, a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, announced completion of an exclusive license agreement for all U.S. rights to Arlevert
Columbus Circle Investors lowered its position in Jazz Pharmaceuticals plc by 24.8% during the third quarter, according to its most recent 13 F filing with the Securities and Exchange Commission. Columbus Circle Investors owned 0.17% of Jazz Pharmaceuticals plc worth $12,565,000 as of its most recent SEC filing. Westpac Banking Corp raised its posi
LOS ANGELES Wednesday AHF lauded the publication of clinical trial results in the journal Lancet which showed 100 percent efficacy in preventing Ebola virus infection among study participants who received an experimental vaccine in Sierra Leone and Guinea. Every year the world collectively spends almost $2 trillion on defense and only $36 billio
Humacyte, an innovator in biotechnology and regenerative medicine, announced today the initiation of a U.S. Phase II arterial bypass clinical trial of HUMACYL, its investigational human acellular vessel, to test the safety and efficacy as a lower extremity arterial bypass vessel in patients with peripheral arterial disease. The initiation of the Ph
Inovio Pharmaceuticals Inc. s stock had its buy rating restated by Stifel Nicolaus in a research note issued to investors on Friday. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, September 14th. HC Wainwright initiated coverage on shares of Inovio Pharmaceuticals in
Leerink Swann set a $182.00 price target on Jazz Pharmaceuticals PLC in a research note issued to investors on Wednesday. BMO Capital Markets restated an outperform rating and set a $195.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Thursday, September 8th. Barclays PLC reaffirmed a buy rating and set a $200.00 price target o
Pharmaceutical company Lupin has received tentative approval from the United States Food and Drug Administration to market its cholesterol lowering Pitavastatin tablets in the American market. has received approval for Pitavastatin tablets in the strength of 1 milligram, 2 mg and 4 mg. Pitavastatin is a generic version of Kowa's Livalo tablets in t
By a News Reporter-Staff News Editor at Marketing Weekly News The biopharmaceutical company Dompe announced the acceptance of the registration application submitted to the European Medicines Agency for Oxervate eye drops, for the treatment of moderate and severe neurotrophic keratitis in adult patients. Acceptance by EMA constitutes the...
This file photo taken on March 10, 2015, shows a woman getting vaccinated at a health center in Conakry, Guinea, during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus. China says its first domestically-developed Ebola vaccine is a major medical breakthrough as it passed the Phase-II clinical test and gains permission for
By a News Reporter-Staff News Editor at Investment Weekly News- Ocugen, Inc., a biopharmaceutical company developing treatments for sight-threatening diseases, announced that it has closed a $6 million round of Series A funding, including $1 million in funds raised through EB5 Life Sciences LP. The EB5 Life Sciences LP offering remains open with
RTW Investments LLC cut its stake in Kite Pharma Inc. by 16.9% during the second quarter, according to its most recent filing with the SEC. RTW Investments LLC owned 0.58% of Kite Pharma worth $14,276,000 as of its most recent SEC filing. BlackRock Fund Advisors boosted its stake in Kite Pharma by 14.6% in the first quarter.
TapImmune, Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today issued its year-end 2016 update. Below is the statement from Glynn Wilson, Ph.D., Chairman and CEO of TapImmune:. As you are well a
Heavy Metal and makeup have more in common than you might know. Lipsticks, mascara, sunblock, and deodorant are just a few of the toxic products that contain levels of heavy metals and other substances that are unregulated by the FDA. Unlike drug companies, cosmetics companies may use almost any ingredients they choose, with few exceptions.
Columbus Circle Investors boosted its stake in Valeant Pharmaceuticals International, Inc. by 24.6% during the third quarter, according to its most recent 13 F filing with the Securities and Exchange Commission. Columbus Circle Investors holdings in Valeant Pharmaceuticals International were worth $3,812,000 at the end of the most recent quarter.
Whey Protein Market for Dietary Supplement, Pharmaceutical and Clinical Nutrition, Bakers and Confectionaries, Snacks and Dairy Products& Others Application: 2015- 2021- Research and Markets. By a News Reporter-Staff News Editor at Investment Weekly News Research and Markets has announced the addition of the "Whey Protein Market for Dietary Suppl
The Ohio Secretary of State certified yesterday 116,015 signatures of registered Ohio voters who support the Ohio Drug Price Relief Act, a proposed statewide ballot initiative that will revise Ohio law to require state programs pay the same or less for prescription medications as the U.S. Department of Veterans Affairs. Drug pricing advocates affil
ALEXANDRIA, Va., Dec. 31 Alexion Pharmaceuticals, Cheshire, Connecticut, has been assigned a patent developed by four co-inventors for "methods of treating complement-associated disorders with anti-C5a antibodies." The co-inventors are Russell P. Rother, Oklahoma City, Douglas L. Sheridan, Branford, Connecticut, Paul P. Tamburini, Kensington, Con
Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies. This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in.